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SIRT1NF-κB is a transcription factor that integrates pro-inﬂammatory and pro-survival responses in diverse cell types.
The activity of NF-κB is regulated in part by acetylation of its p65 subunit at lysine 310,which is required for tran-
scription complex formation. De-acetylation at this site is performed by sirtuin 1(SIRT1) and possibly other
sirtuins in an NAD+ dependent manner, such that SIRT1 inhibition promotes NF-κB transcriptional activity. It
is unknown, however, whether changes in NAD+ levels can inﬂuence p65 acetylation and cellular inﬂammatory
responses. Poly(ADP-ribose)-1 (PARP-1) is an abundant nuclear enzyme that consumes NAD+ in the process of
forming (ADP-ribose)polymers on target proteins, and extensive PARP-1 activation can reduce intracellular
NAD+ concentrations. Herewe tested the idea that PARP-1 activation can regulate NF-κB transcriptional activity
by reducing NAD+ concentrations and thereby inhibiting de-acetylation of p65. Primary astrocyte cultures were
treated with the alkylating agent N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) to induce PARP-1 activation.
This resulted in sustained acetylation of p65 and increased NF-κB transcriptional activity as monitored by a
κB-driven eGFP reporter gene. These effects of MNNG were negated by a PARP-1 inhibitor, in PARP-1−/− cells,
and in PARP-1−/− cells transfected with a catalytically inactive PARP-1 construct, thus conﬁrming that these
effects are mediated by PARP-1 catalytic activity. The effects of PARP-1 activation were replicated by a SIRT1 in-
hibitor, EX-527, and were reversed by exogenous NAD+. These ﬁndings demonstrate that PARP-1-induced
changes in NAD+ levels can modulate NF-κB transcriptional activity through effects on p65 acetylation.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
NF-κB is a transcription factor that integrates pro-inﬂammatory
and pro-survival responses in diverse cell types. NF-κB is activated
by numerous stimuli including DNA damage, which can occur as a
direct secondary effect of infection, ischemia, trauma, and other
stressors [1]. The NF-κB family includes ﬁve members, p65 c-Rel,
RelB, p105/p50 and p100/p52 that form homo- or heterodimers [2].
In most cell types, the most abundant heterodimer consists of p65
and p50. The regulation of NF-κB activity is complex, and occurs at
multiple levels [2]. One level of regulation in canonical NF-κB activa-
tion involves the release of p65/p50 dimers from the IκB subunit in
the cytosol, and subsequent translocation to the nucleus. A secondhistone deacetylases; MNNG,
ose); PARP-1, poly(ADP-ribose)
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rights reserved.layer of regulation occurs within the nucleus, with the formation of
an active transcription complex. p300/CBP mediated acetylation of
various lysine sites (at least 5 sites reported) of the p65 subunit
has been established as a key regulatory event in this process. In par-
ticular, acetylation at lysine 310 of p65 is required for full transcrip-
tional activity of p65, while acetylation at lysine 218/221 enhances
DNA binding and impairs assembly with IκBα [3,4]. Acetylation of
these lysine sites can be reversed by histone deacetylase (HDAC) core-
pressor proteins [5,6]. Deacetylation of p65 lysine 218/221 does not re-
quire NAD, but Lysine 310 of p65 is deacetylated in the nucleus by the
atypical class III HDACs, SIRT1 and possibly other sirtuins in a reaction
that requires NAD+ [3,4,7,8].
NAD+ is also required by the abundant nuclear enzyme, poly(ADP-
ribose) polymerase-1 (abbreviated as PARP-1). Upon activation by DNA
damage, cytokines, or other signals, PARP-1 consumes NAD+ to gen-
erate branched ADP-ribose polymers on chromatin and other accep-
tor proteins [9,10]. These polymers have diverse functions in DNA
repair and other nuclear processes [11,12]. Extensive PARP-1 activation
can deplete the cytosolic (non-mitochondrial) NAD+ pool ([13–16].
PARP-1 also regulates NF-κB activity [17,18], but there remains uncer-
tainty as to the role of PARP-1 activity in this process. Several studies
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mediated responses [19–24], whereas others have found that PARP-1
inﬂuences NF-κB-mediated responses independent of its enzymatic ac-
tivity [17,25–27].
Given that both SIRT1 and PARP-1 require NAD+, one mechanism
by which PARP-1 activation could inﬂuence NF-κB activity is by
reducing the amount of NAD+ available for SIRT1 de-acetylation of
p65 [28]. Here we tested this hypothesis using primary astrocyte
cultures in which PARP-1 activation was induced by the DNA alkylating
agent N-methyl-N′-nitro-N-nitrosoguanidine (MNNG). Astrocytes are
experimentally convenient because they are non-neoplastic cells that
can be prepared in homogeneous cultures, and because prior work has
established key aspects of PARP-1 activation and regulation in this cell
type. Results of the present studies conﬁrm that extensive PARP-1 activa-
tion promotes NF-κB transcriptional activation by amechanism involving
p65 acetylation.
2. Materials and methods
2.1. Materials
Cell culture reagents were obtained from Cellgro/Mediatech (Hern-
don,VI). 3,4-dihydro-5-[4-(1-piperidinyl)butoxy]-1(2h)-isoquinolinone
(DPQ)was obtained from Calbiochem (San Diego, CA). All other reagents
were from Sigma/Aldrich (St. Louis, MO) except where otherwise stated.
2.2. Cell cultures
All animal studies were approved by the San Francisco Veterans
Affairs Medical Center animal studies committee and follow the NIH
guidelines for humane care of animals. PARP-1−/−mice were obtained
from the Jackson Labs and out bred for more than 10 generations to the
CD1 background. Wild type mice were from the closely related Swiss
Webster strain and were obtained from Simonsen Labs (Gilroy, CA).
Astrocyte cultures were prepared from mouse pups of both sexes
in 24-well plates as described previously [29]. At conﬂuency (12–
14 days in vitro), the cultures were treated with 22 μM cytosine
β-D-arabinofuranoside for 2 days to inhibit the proliferation of microg-
lia. The cultures were subsequently maintained in Eagle's minimal es-
sential medium (MEM) supplemented with 3% fetal bovine serum
(FBS).
2.3. Cell culture experiments
Studies were initiated by placing the astrocyte cultures in a phys-
iological balanced salt solution (BSS) containing 3.1 mM KCl, 134 mM
NaCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 0.5 mM KH2PO4, 15.7 mM
NaHCO3 and 2 mM glucose, pre-equilibrated to pH 7.2 in a 5% CO2 at-
mosphere. Experiments were performed at 37 °C in 5% CO2 with test
compounds prepared as concentrated stock solutions in BSS. Stimula-
tions with 100 μM MNNG for 10 min were terminated by complete
medium exchange and replacement with BSS. Control wells received
medium exchanges only.
2.4. Immunostaining
Fixation and immunostaining of cell cultures were performed as
previously described [23]. Incubations were performed with a 1:1000
dilution of rabbit anti-poly(ADP-ribose) (Trevigen, Gaithersburg, MD),
or with 1:30 dilution of rabbit polyclonal anti-NF-κB p65 (Cell Signaling
Technology, Inc., Danvers, MA) at 4 °C for 24 h, followed by incubation
with Alexa Fluor 594-conjugated anti-rabbit IgG (Molecular Probes,
Eugene, OR), 1:500 dilution, for 2 h. For evaluation of NF-κB nuclear
translocation, nuclei were stained with propidium iodide. Confocal
photomicrographs were obtained from single layer scan with pinholeof 1 Airy (~100 μm). Controls prepared in the absence of primary anti-
body showed no staining under the conditions described (not shown).
2.5. Western blotting
Western blots from whole cell samples were prepared and
quantiﬁed as described [23]. Membranes were incubated with 1:200
dilutions of rabbit anti-NF-κB Ac-p65 (acetyl K310; Abcam, Inc.
Cambridge, MA), 1:2500 dilution of rabbit polyclonal anti-NF-κB (p65;
Calbiochem/EMD Bioscience, Inc., La Jolla, CA) or with a 1:500 dilution
of mouse monoclonal anti-poly(ADP-ribose) (clone 10HA; Trevigen,
Gaithersburg, MD). After washing, the membranes were incubated for
2 h with peroxidase-conjugated anti-rabbit or anti mouse IgG (Vector
Laboratories, Burlingame, CA) diluted 1:7500. The protein bands were
visualized using ECL™ Plus WB Detection kit (Amersham-Pharmacia
Biotech) and X-OMAT AR ﬁlm (Kodak). To quantify protein loading,
the membranes were re-probed with mouse monoclonal anti β-actin
at a 1:10,000 dilution, followed by peroxidase-conjugated anti-mouse
IgG (1:10,000 dilution). Controls performed in the absence of primary
or secondary Abs showed no signal (data not shown). Band densities
were quantiﬁed with the NIH Image J program.
2.6. Cell transfections
Wild-type and mutant human PARP-1 constructs were prepared as
previously described [30]. PARP-1−/− mouse cells were transfected at
8–9 days in vitro, at about 90% conﬂuency, using Lipofectamine 2000
(Invitrogen) at a 2:1 ratio with DNA. Cells were used for experiments
40–48 h after transfection. The lentivirus κB-dEGFP construct was pre-
pared as described previously [31] and astrocytes were treatedwith the
lentivirus 2–3 days prior to experiments. eGFP expression was evaluat-
ed by ﬂuorescence microscopy at the designated time points after
MNNG exposure by counting the number of eGFP-expressing cells in 5
randomly selected ﬁelds within each culture well.
2.7. Statistics
Each “n”denotes an independent experiment comprised of 3–4 paral-
lel treatments per condition. Results are presented as amean ± standard
error. Statistical signiﬁcance was evaluated by one-way ANOVA followed
by the Dunnett's test formultiple comparisons against a common control
group.
3. Results
3.1. PARP-1 inhibition prevents NF-κB p65 acetylation
Astrocyte cultures treated for 10 min with the alkylating agent
MNNG (100 μM) developed a robust activation of PARP-1 (Fig. 1).
PAR immunoreactivity appears as a smear in these Western blots,
indicating poly(ADP-ribosylation) of many different protein tar-
gets [32,33]. This signal was completely blocked by the addition
of the PARP inhibitor DPQ, but was unaffected by the addition of
NAD+ (Fig. 1). MNNG treatment also induced acetylation of p65
NF-κB subunit (Fig. 2A). The increase in p65 acetylation was blocked
by both pharmacological PARP inhibition (DPQ) and by genetic PARP-1
deletion (Fig. 2B, C, D).
3.2. NAD+ inﬂuences NF-κB acetylation
Our prior studies have established that MNNG-induced PARP-1
activation under the conditions of these experiments causes a rapid
and sustained depletion of cytosolic NAD+ (from 9.51 ± 0.72 to
2.85 ± 0.93 nmol/mg protein) [14]. We also previously demonstrat-
ed that this depletion can be reversed by medium supplementation
with 2.5 mM NAD+, which gains entry into astrocytes through
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Fig. 1.MNNG-induced PARP-1 activation is blocked by DPQ, but not NAD+. Immunoblots
show formation of poly(ADP-ribose)-conjugated proteins (PAR). A, Ten-minute incuba-
tions with 100 μMMNNG induce robust PAR formation that is prevented by the PARP-1
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Fig. 2. NF-κB subunit p65 acetylation is affected by PARP-1 activation and NAD+ levels.
A, MNNG (100 μM for 10 min) induces acetylation of NF-κB p65 in wild-type (wt) as-
trocytes. B, MNNG does not induce p65 acetylation in PARP-1 deﬁcient astrocytes.
C, MNNG induced p65 acetylation in wt astrocytes is blocked by both the PARP inhib-
itor DPQ (25 μM) and by medium supplementation with NAD+ (2.5 mM). Time points
denote intervals following washout of MNNG. D, Graph shows quantiﬁed data of p65
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substrate for SIRT1 de-acetylation of p65, we evaluated the possibility
that PARP-1 activation increases p65 acetylation and resultant NF-κB
transcriptional activation by impairing the ability of SIRT1 or other
NAD+-dependent sirtuins to de-acetylate p65 (Fig. 3A). Consistent
with this idea, 2.5 mM NAD+ was found to prevent the MNNG-
induced increase in p65 acetylation (Fig. 2C, D). This effect cannot be
attributed to PARP-1 inhibition by NAD+ or NAD+metabolites because
NAD+ supplementation did not block PARP-1 activity (Fig. 1B). More-
over, NAD+ was found to have no effect on p65 acetylation when
SIRT1 activity was blocked by 10 μM EX-527 [35,36] (Fig. 3B).
3.3. PARP-1 enzymatic activity is required for NF-κB transcriptional
activation
Activation of NF-κB signaling was further evaluated in astrocytes
transfected with a κB reporter gene that responds to NF-κB (p65)
transcriptional activation by expressing enhanced green ﬂuorescent
protein (eGFP) [31]. Inhibition of SIRT-1 activity with EX-527 in-
creased eGFP expression in concert with increased p65 acetylation
(Fig. 3C, D). MNNG exposure similarly increased NF-κB transcription-
al activity in wild-type astrocytes, but not in PARP-1−/− astrocytes or
wild-type astrocytes treated with the PARP inhibitor DPQ. MNNG also
failed to induce NF-κB activation in cultures supplemented with
2.5 mM NAD+ (Fig. 4A, C).
The role of PARP-1 enzymatic activity in NF-κB activation was
further evaluated by using previously developed PARP-1 mutants
containing modiﬁcations at phosphorylation sites that inﬂuence en-
zymatic activity [30]. PARP-1−/− cells transfected with wild-type
PARP-1 and treated with MNNG showed eGFP expression in about
30% of the cells. Prior studies have shown comparable transfection
efﬁciency attained with all 3 constructs used [30]. PARP-1−/− cellstransfected with S372A & T373A PARP-1, which lacks phosphorylation
sites required for enzymatic activation, failed to show NF-κB activation
after MNNG stimulus. Conversely, PARP-1−/− cells transfectedwith the
S372E PARP-1 mutant, which mimics constitutive phosphorylation at
this site, showed increased NF-κB activation even in the absence of
MNNG stimulation (Fig. 4B, D). Additional studies conﬁrmed that the
impaired NF-κB transcription activity in PARP-1−/− cells is not due to
deﬁcient p65 protein expression (Fig. 5A), and that PARP-1 depletion
does not either interfere withNF-κB p65 nuclear translocation (Fig. 5B).
4. Discussion
These results show that extensive activation of PARP-1 can pro-
mote the transcriptional activity of NF-κB by a mechanism involving
p65 acetylation. Reversal of this effect by exogenous NAD+, in con-
junction with previously demonstrated effects of PARP-1 and exoge-
nous NAD+ on intracellular NAD+ levels, identify this as an NAD+
dependent mechanism. At present, the only enzymes known to per-
form NAD+-dependent de-acetylation of lysine residues are the
class III histone de-acetylases, also known as sirtuins [37]. SIRT1 in
particular can catalyze de-acetylation of the lysine 310 of p65 [31].
SIRT2 has also been reported to do so [8], but SIRT2 is not usually
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1989T.M. Kauppinen et al. / Biochimica et Biophysica Acta 1833 (2013) 1985–1991localized to the nucleus. However, there is presently no way to direct-
ly evaluate in situ SIRT1 activity (other than by p65 acetylation), so
we cannot exclude the possibility that NAD+ levels inﬂuence p65
acetylation by some other, as yet unrecognized mechanism.
PARP-1 activation not only consumes NAD+, but also produces
nicotinamide as a product of NAD+ cleavage. The production of nic-
otinamide has been suggested as another possible way that PARP-1
and sirtuins may interact, because many sirtuins (including SIRT1)
are inhibited by nicotinamide [37,38]. The expected effect of nicotin-
amide in this instance would be prolonged p65 acetylation andenhanced NF-κB transcriptional activation, as was observed here.
However, the additional observation that exogenous NAD+ supple-
mentation did not inhibit PARP-1 activity while was still able to
reverse the effects of PARP-1 on both p65 acetylation and NF-κB
transcriptional activity argues against the idea that cleavage of
NAD+ to nicotinamide or other metabolites is a signiﬁcant regulato-
ry factor under these conditions. This notion is further supported by
our previously published data, in which NAD+ supplementation
(5 mM) failed to increase intracellular levels required for PARP-1
inhibition [15].
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Fig. 5. PARP-1 depletion does not affect NF-κB p65 expression or nuclear translocation. A, Immunoblots showing p65 expression in wild-type and PARP−/− cells. B, Confocal images
demonstrate NF-κB p65 subunit nuclear translocation 30 min after MNNG stimulation (100 μM for 10 min) in both wild-type and PARP-1−/− cells. Representative of n = 3.
1990 T.M. Kauppinen et al. / Biochimica et Biophysica Acta 1833 (2013) 1985–1991Canonical NF-κB transcriptional activation requires both transloca-
tion of NF-κB dimers to the nucleus and the subsequent formation
and maintenance of a DNA-bound transcriptional complex. Under the
conditions of MNNG-induced DNA damage employed here, NF-κB
translocation is likely induced by the ATM/NEMO pathway leading to
IκBphosphorylation [39–41]. The role of PARP-1 activation inNF-κB sig-
naling has been demonstrated in many levels, PARP-1 promotes com-
plex formation [19,22,42], participates in DNA binding of p65 subunit
[26], is involved in IKK complex activation [43], and regulates NF-κB
translocation between cytosol and nucleus [44–46]. In our model
PARP-1 depletion did not prevent cytosol-to-nucleus translocation of
NF-κB (p65) but NF-κB transcriptional activity was prevented. This
ﬁnding underscores the fact that p65 nuclear translocation is not func-
tionally equivalent to transcriptional activation. Our results point to the
ability of PARP-1 to affect activity of other enzymes regulating NF-κB
signaling. This ﬁnding is consistent with the model proposed (Fig. 3A),
and underscores the importance of NAD+ in PARP-1 mediated NF-κB
regulation.
The role of PARP-1 enzymatic activity in the regulation of NF-κB is
also addressed by these studies. Astrocytes transfectedwith the catalyt-
ically inactive PARP-1 construct failed to show increased NF-κB tran-
scriptional activity in the presence of MNNG, and wild type astrocytes
treated with the PARP inhibitor, DPQ, similarly failed to show increased
NF-κB transcriptional activity. These results agree with those of several
prior studies that demonstrate that catalytic PARP-1 inhibition sup-
presses variety of NF-κB-mediated responses [17,20,22,23,45,47–51].
However, these results do not exclude the possibility that PARP-1 may
also interact with NF-κB by non-enzymatic mechanisms. Strong evi-
dence for this possibility exists [46,52], including evidence for a physical
association between PARP-1 and the p65 subunit [26]. Such a mecha-
nism has already been demonstrated with p53 [53], which shares in-
triguing similarities with PARP-1 mediated NF-κB regulation [45].
The present studies were performed under conditions of extensive
PARP-1 activation, such as those that occur during oxidative stress or
excitotoxicity. As such, they provide proof of principle that PARP-1 me-
diated depletion of NAD+, as occurs during genotoxic stress, is capable
of inﬂuencing NF-κB transcriptional activity. However, it remains to be
established whether this is an active mechanism during more physio-
logical PARP-1 activation. The SIRT1 Km for NAD+ is near the estimated
cytosolic NAD+ concentration [54], suggesting that even modest levels
of PARP-1 activation could inﬂuence NF-κB transcriptional activity bythis mechanism. Recent work evaluating the effects of PARP-1 and
SIRT1 on fat and muscle metabolism supports this contention [55].
5. Conclusions
PARP-1 activation can regulate NF-κB transcriptional activity by
reducing NAD+ concentrations and thereby inhibiting deacetylation
of p65. This observation identiﬁes a novel mechanism by which
DNA damage can promote NF-κB transcriptional activity.
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